Another OX40 therapy drops out of the race

AbCellera has discontinued development of its OX40 receptor-blocking antibody for autoimmune conditions despite successful Phase 1 results, following similar withdrawals by other pharma companies citing safety concerns. Meanwhile, the US HHS is funding ibogaine research for PTSD and serious mental illnesses, and Ossium Health reported the first bone marrow transplant using deceased donor marrow for aplastic anemia.

This Wire brief sits within Fusion42's coverage of Biotech.